bet9九州网址

  • <kbd id="sdring" ><rt id="sdring" ><bdo id="sdring" ></bdo></rt></kbd>
  • <source id="sdring" ></source>

    <b id="sdring" ></b>
  • <b id="sdring" ><acronym id="sdring" ><meter id="sdring" ></meter></acronym></b>

        <del id="sdring" ></del>
        Log in
        E-mail
        Password
        Remember
        Forgot password ?
        Become a member for free
        Sign up
        Sign up
        New member
        Sign up for FREE
        New customer
        Discover our services
        Settings
        Settings
        Dynamic quotes 

        MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

        REGENERON PHARMACEUTICALS

        (REGN)
          Report  
         SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
        Quotes 5-day view   Delayed Quote. Delayed Nasdaq
        11/05/2019 11/06/2019 11/07/2019 11/08/2019 11/11/2019 Date
        332.6(c) 324.49(c) 326.39(c) 341.79(c) 344.28(c) Last
        2 345 712 1 017 717 952 368 1 106 222 611 923 Volume
        +6.93% -2.44% +0.59% +4.72% +0.73% Change
        More quotes
        Financials (USD)
        Sales 2019 7 780 M
        EBIT 2019 2 258 M
        Net income 2019 1 957 M
        Finance 2019 5 371 M
        Yield 2019 -
        Sales 2020 8 358 M
        EBIT 2020 2 868 M
        Net income 2020 2 466 M
        Finance 2020 6 940 M
        Yield 2020 -
        P/E ratio 2019 18,9x
        P/E ratio 2020 15,0x
        EV / Sales2019 3,87x
        EV / Sales2020 3,41x
        Capitalization 35 474 M
        More Financials
        Company
        Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (61.2%); - supply of collaborative services (32.6%): working with Sanofi... 
        Sector
        Biotechnology & Medical Research
        Calendar
        11/12 | 10:00amPresentation
        More about the company
        Surperformance© ratings of Regeneron Pharmaceuticals
        Trading Rating : Investor Rating :
        More Ratings
        Latest news on REGENERON PHARMACEUTICALS
        07:31aREGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentations
        PR
        11/06REGENERON PHARMACEUTICALS : to Report Results from CD20xCD3 and BCMAxCD3 Bispeci..
        PU
        11/06REGENERON PHARMACEUTICALS : Provides Updates on Phase 3 Libtayo Development Prog..
        AQ
        11/06Biogen Adding Ophthalmology Biosimilars in Deal With Samsung Bioepis
        DJ
        11/06REGENERON PHARMACEUTICALS : and Vyriad Announce Strategic Agreement for Discover..
        PR
        11/05Regeneron Pharmaceuticals Up Over 9%, on Pace for Largest Percent Increase Si..
        DJ
        11/05REGENERON PHARMACEUTICALS : Board Approves $1 Billion Buyback
        DJ
        11/05REGENERON PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
        AQ
        11/05REGENERON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition,..
        AQ
        11/05Regeneron Pharmaceuticals Reports Higher 3Q Profit
        DJ
        11/05REGENERON : 3Q Earnings Snapshot
        AQ
        11/05REGENERON PHARMACEUTICALS : Provides Updates on Phase 3 Libtayoョ (cemiplimab) De..
        PR
        11/05REGENERON PHARMACEUTICALS : Reports Third Quarter 2019 Financial and Operating R..
        PR
        10/31REGENERON PHARMACEUTICALS, INC. : quaterly earnings release
        10/30REGENERON PHARMACEUTICALS : Dupixent Now Approved in European Union for Severe C..
        AQ
        More news
        News in other languages on REGENERON PHARMACEUTICALS
        11/07WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
        11/05WALL STREET STOCK EXCHANGE : L'optimisme sur le commerce porte de nouveau Wall S..
        11/05Les valeurs à suivre aujourd'hui à Wall Street Mardi 5 novembre 2019
        11/05REGENERON : bat le consensus grâce à Dupixent
        11/05WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
        More news
        Analyst Recommendations on REGENERON PHARMACEUTICALS
        More recommendations
        Sector news : Bio Therapeutic Drugs
        11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
        DJ
        11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
        DJ
        11/06CELLTRION : 3Q Net Profit Rose 13% on Year
        DJ
        11/05SoftBank's Tech Problems Widen -- WSJ
        DJ
        11/04Snakes and ladders - SoftBank Vision Fund's climbing, sliding valuations
        RE
        More sector news : Bio Therapeutic Drugs
        Chart REGENERON PHARMACEUTICALS
        Duration : Period :
        Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
        Full-screen chart
        Technical analysis trends REGENERON PHARMACEUTICALS
        Short TermMid-TermLong Term
        TrendsBullishBullishNeutral
        Income Statement Evolution
        Consensus
        Sell
        Buy
        Mean consensus OUTPERFORM
        Number of Analysts 24
        Average target price 381,91  $
        Last Close Price 324,49  $
        Spread / Highest target 57,2%
        Spread / Average Target 17,7%
        Spread / Lowest Target -2,92%
        EPS Revisions
        Managers
        NameTitle
        Leonard S. Schleifer Co-President, Chief Executive Officer & Director
        George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
        P. Roy Vagelos Chairman
        Robert E. Landry Chief Financial Officer & Executive VP-Finance
        Michael S. Brown Independent Director
        Sector and Competitors
        1st jan.Capitalization (M$)
        REGENERON PHARMACEUTICALS-7.82%35 474
        GILEAD SCIENCES3.34%82 753
        VERTEX PHARMACEUTICALS21.84%50 394
        WUXI APPTEC CO., LTD.73.35%21 914
        GENMAB40.89%14 081
        BEIGENE, LTD.36.69%11 493
        bet9九州网址

            ,